OptiNose Inc. reports news centered on XHANCE, its FDA-approved drug-device combination product for adults with chronic rhinosinusitis with or without nasal polyps. XHANCE uses the Exhalation Delivery System to deliver fluticasone propionate to high and deep regions of the nasal cavity where sinuses ventilate and drain.
Company updates commonly cover XHANCE net revenue, prescription trends, financial results, commercial execution with ear, nose and throat and allergy specialists, and operating highlights. OptiNose news also includes corporate presentations, material agreements, shareholder voting matters, and capital-structure actions related to its public listing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.